Ventirx Pharmaceuticals, Inc.

Cavion, Inc.

Embera Neurotherapeutics, Inc.

Muralikrishna Duvvuri

J Jeffry Howbert

Robert Hershberg

Gregory Dietsch

Margaret S Lee

Michelle S Higgin

Spyridon Papapetropoulos

Bruce N Rehlaender

Evan Newbold

Julie A Straub

Winston A Vadino

Bruce Rehlaender

Kripanath Borah

Carol Gloff

Jay Breaux

Parag M Ved

Rob Hershberg

Greg Dietsch

This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.

Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Provided are pharmaceutical compositions useful for the treatment and/or prevention of a disorder, such as addiction. For example, pharmaceutical compositions are provided that comprise a first active pharmaceutical component (e.g., metyrapone) and a second active pharmaceutical component (e.g., oxazepam). The compositions may be constructed in such a manner as to limit the physical contact between the first and second active pharmaceutical components, thus preventing any degradation of the active pharmaceutical components resulting form interaction between the two components. The compositions may include at least one pharmaceutically acceptable excipient. Also provided are methods of making the compositions as well as kits containing materials to provide the compositions.

Pharmaceutical compositions and uses thereof

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.

Toll-like receptor agonist formulations and their use

Growing community of inventors

Chapel Hill, NC, United States of America

Muralikrishna Duvvuri